S-1/A: Metagenomi Files for IPO, Aiming to Raise Up to $100 Million for Genetic Medicine Development

Metagenomi, a precision genetic medicines company, has filed an S-1/A form to register 6,250,000 shares of common stock for an initial public offering, with an expected price between $15.00 and $17.00 per share.

Summary

• Metagenomi, Inc. is planning an initial public offering of 6,250,000 shares of its common stock.
• The expected initial public offering price is between $15.00 and $17.00 per share.
• The company has applied to list its common stock on the Nasdaq Global Select Market under the symbol MGX.
• Metagenomi is an emerging growth company and a smaller reporting company, which allows it to comply with certain reduced public company reporting requirements.
• The company intends to use the net proceeds from the IPO to continue research and development of its therapeutic portfolio, advance IND-enabling studies and filings, advance its gene editing platform, and for general corporate purposes.
• Metagenomi's platform is designed to discover and develop novel genome editing tools for curative therapeutics.
• The company's lead programs focus on hemophilia A, primary hyperoxaluria type 1 (PH1), and transthyretin amyloidosis (ATTR).

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both the potential of Metagenomi's technology and the risks associated with its business. The sentiment is cautiously optimistic, reflecting the early stage of the company and the inherent uncertainties in the biotechnology industry.

Positives

• The company's platform is designed to discover and develop novel genome editing tools for curative therapeutics.
• The company's lead programs target hemophilia A, PH1, and ATTR, with plans to expand into neurodegenerative and neuromuscular diseases.
• An ongoing NHP study for hemophilia A demonstrated therapeutically relevant levels of cyno-FVIII protein for 4.5 months following a single dose.
• The company is in advanced stages of nuclease and guide selection for ATTR, having achieved more than 90% knockdown of human TTR protein in a humanized TTR mouse model.

Negatives

• The company has incurred significant losses since inception and expects to continue to incur losses for the foreseeable future.
• The company has never generated revenue from product sales and may never become profitable.
• The company is very early in its development efforts and has not yet initiated IND-enabling studies or clinical development of any product candidates.
• The genome editing field is relatively new and evolving rapidly, and other genome editing technologies may be discovered that provide significant advantages over Metagenomi's technologies.

Risks

• The company may not be able to raise additional capital when needed on acceptable terms, or at all.
• The company may be unable to advance its product candidates into and through clinical trials, obtain regulatory approval, and ultimately commercialize its product candidates.
• The company is subject to additional development challenges and risks due to the novel nature of its genome editing technology.
• Clinical drug development involves a lengthy and expensive process, with an uncertain outcome.
• The regulatory landscape that will govern the company's potential product candidates is uncertain and may change.
• The company faces significant competition in an environment of rapid technological change.
• If conflicts arise between the company and its collaborators or strategic partners, these parties may act in a manner adverse to the company.
• The company's commercial success depends on its ability to obtain, maintain, enforce, and otherwise protect its intellectual property and proprietary technology.

Future Outlook

Metagenomi expects that the net proceeds from this offering, together with its existing cash and cash equivalents and available-for-sale marketable securities, will be sufficient to fund its operating expenses and capital expenditure requirements into 2027.

Management Comments

• The company is driven by a passion to create potentially curative genetic medicines through the discovery of novel genome editing technologies by harnessing the power of metagenomics.
• The company aims to match the optimal genome editing tools for each indication.
• The company intends to deliver a full copy of a functional CFTR gene, as opposed to currently-available therapies limited to subsets of patients with individual mutations.

Industry Context

The document places Metagenomi within the competitive landscape of genetic medicine, highlighting its unique approach using metagenomics to discover novel genome editing tools. It acknowledges competition from companies using CRISPR/Cas technology, zinc finger nucleases, and other gene therapy approaches. The document emphasizes the potential for Metagenomi's platform to overcome limitations of existing technologies, such as targetability, specificity, and delivery.

Comparison to Industry Standards

• The document compares Metagenomi's approach to existing therapies for hemophilia A, PH1, and ATTR, highlighting the limitations of current treatments and the potential advantages of Metagenomi's gene editing strategies.
• For hemophilia A, the document contrasts Metagenomi's FVIII knock-in approach with AAV gene therapy, which has shown declining FVIII levels over time.
• For PH1, the document positions Metagenomi's durable HAO1 knockdown as a potential improvement over siRNA therapies that require repeat administration.
• The document compares the size and targetability of Metagenomi's nucleases to SpCas9, noting that Metagenomi's SMART nucleases are smaller and can target a broader range of genomic sites.
• The document mentions that other companies such as Tessera Therapeutics, Inc. and Tome Biosciences, Inc. have announced their work in recombinase DNA and RNA gene writers, although little is known publicly about their science or portfolio.

Stakeholder Impact

• Shareholders: The IPO provides an opportunity for new investors to participate in the company's growth, while existing shareholders may experience dilution.
• Employees: The company's growth and success could lead to increased job opportunities and career advancement for employees.
• Patients: The company's development of new genetic medicines could provide new treatment options and potentially cures for patients with genetic diseases.
• Collaborators: The company's collaborations with other companies could lead to new partnerships and opportunities for growth.
• Creditors: The company's financial stability and ability to repay its debts could be affected by the success of the IPO and its future operations.

Next Steps

• The company intends to continue measuring FVIII levels in monkeys up to the 12-month time point to generate a robust data set on durability for the hemophilia A program.
• The company anticipates a development candidate selection for hemophilia A in Q2 2024.
• The company expects to have NHP data in 2024 to support final development candidate selection for PH1.
• The company expects to move into NHP studies for ATTR in 2024.
• The company plans to move into NHP studies for ATTR in 2024.
• The company plans to move into NHP studies for ATTR in 2024.
• The company plans to perform a second NHP integration study to select a single donor and guide and expects to nominate a development candidate for hemophilia A by Q2 2024.
• The company is initiating GxP manufacturing of mRNA, gRNA, AAV and LNP to support future IND-enabling studies for hemophilia A.
• The company is in the final stages of confirming the candidate to take into NHP studies for PH1.
• The company is in advanced stages of nuclease and guide selection for ATTR and expects to move into NHP studies in 2024.
• The company is in advanced stages of nuclease and guide selection for cardiovascular disease and expects to move into NHP studies in late 2024 or early 2025.
• The company is in the process of optimizing AAV vector designs to package and efficiently express its small nucleases and gRNA from a single virus to enable evaluation of lead SOD1 and ATXN2 guides in mouse models for familial ALS.

Key Dates

Keywords

Metagenomi, IPO, genome editing, genetic medicines, therapeutics, clinical trials, research and development, Moderna, Ionis, Affini-T, hemophilia A, PH1, ATTR, nucleases, base editing, RIGS, CASTs, LNP, AAV